Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001542482 | SCV003508764 | likely pathogenic | Hereditary spastic paraplegia 49 | 2024-02-09 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 11 of the TECPR2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TECPR2 are known to be pathogenic (PMID: 23176824, 25590979). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with TECPR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1184452). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Fulgent Genetics, |
RCV001542482 | SCV005637434 | likely pathogenic | Hereditary spastic paraplegia 49 | 2024-04-23 | criteria provided, single submitter | clinical testing | |
| Genomics England Pilot Project, |
RCV001542482 | SCV001760327 | likely pathogenic | Hereditary spastic paraplegia 49 | no assertion criteria provided | clinical testing |